Adults and teenagers who have a genetic condition called hereditary angioedema (HAE) may receive Cinryze. This prescription medicine is used to prevent HAE attacks, which cause pain and swelling beneath the skin. It is given as an injection into a vein every three or four days. Side effects include headaches, nausea, and vomiting.
Cinryze® (C1 esterase inhibitor) is a prescription medication approved to prevent hereditary angioedema (HAE) attacks in adults and teenagers. HAE is a rare genetic condition that causes sudden swelling and painful attacks of various body parts.
Cinryze is a C1 esterase inhibitor. It contains the same active component as Berinert®, another C1 esterase inhibitor. Berinert is approved to treat HAE attacks once they occur.
Cinryze is made by Sanquin Blood Supply Foundation for ViroPharma Biologics, Inc.
HAE is caused by a defect in the gene that controls a protein known as C1 inhibitor. C1 inhibitor helps regulate certain complex reactions in the body, including reactions that lead to the production of bradykinin. Bradykinin is a chemical that causes blood vessels to dilate (widen) and leak fluid into surrounding tissue. It is this leakage of fluid that is thought to cause the swelling and painful attacks associated with HAE.
In people with HAE, the body either does not produce enough C1 inhibitor or produces C1 inhibitor that does not function properly. As a result, too much bradykinin is produced, blood vessels leak fluid, and swelling and painful attacks can occur.
Cinryze works by replacing C1 inhibitor that is missing or not working properly in people with HAE, thereby preventing attacks from occurring.